Majd M. AlBarakat
@Majd_BKT
Followers
328
Following
3K
Media
36
Statuses
588
Medical Student | JUST
Hashemite Kingdom of Jordan
Joined February 2021
Closing out my #Transplant #Surgery elective at Medical college of #Wisconsin /#Froedtert Hospital with a heart full of gratitude. ❤️ Learned more than I imagined and was inspired daily by an exceptional team. Thankful for every moment. #MCW
0
0
5
Honored to finish my #Trauma Surgery elective at MetroHealth / Case Western, Cleveland’s premier Level I Trauma Center. Nonstop learning, high-acuity cases, and world-class mentorship — an experience to remember! #Surgery #CaseWestern #Metrohealth #MedTwitter
1
1
26
3/ However, there was no significant difference in #Mortality or #AcuteRenalFailure. More high-quality, standardized trials are needed to refine perfusion strategies in #CardiacSurgery. #CriticalCare #CardiovascularResearch
1
0
1
2/ Across 33 randomized controlled trials, pulsatile perfusion was linked to: ✅ Lower #Creatinine & #Lactate ✅ Higher #CreatinineClearance ✅ Shorter #ICU stay, #HospitalStay & #Intubation time #EvidenceBasedMedicine #ClinicalResearch
1
0
0
🧵1/ Thrilled to share our new publication in PLOS ONE! We conducted a meta-analysis comparing #Pulsatile vs #NonPulsatile perfusion in patients undergoing #CardiopulmonaryBypass 🫀 🔗 https://t.co/gM7CNalEOy
#CardiacSurgery #Perfusion #MetaAnalysis #Research
journals.plos.org
Background Pulsatile perfusion is a developing technique that attempts to mimic the natural pulsatile flow of blood during cardiopulmonary bypass (CBP). Purpose This systematic review and meta-anal...
1
0
2
اللهم إني توكلت عليك وسلمت أمري إليك لا ملجأ ولا منجأ منك إلا إليك
1
0
10
{فَلَا تَعْلَمُ نَفْسٌ مَّا أُخْفِيَ لَهُم مِّن قُرَّةِ أَعْيُنٍ جَزَاءً بِمَا كَانُوا يَعْمَلُونَ}
9
955
4K
📢 New publication! In 1,395 isolated CABG patients, we identified predictors for temporary epicardial pacing wire use. ✅ Pre-op BBB ↑ TCP risk ✅ Post-op complications ↑ TCP risk ✅ Beta-blockers were protective ➡ Supports selective, risk-based PW placement
1
0
3
🔗 : [ https://t.co/xTdjRA1bKu] 👏 Grateful to this brilliant team and our mentor @arvind_kunadi
0
0
0
🧠 Conclusion: Tebentafusp shows modest survival benefits and manageable side effects. ⚠️ CRS and fatigue require proactive clinical management. Still, a promising step forward in treating metastatic uveal melanoma.
1
1
2
📈 Key Results: 🔹 1-year overall survival: 68% 🔹 Cytokine release syndrome (CRS): 83% 🔹 Fatigue: Frequently reported 🟡 Moderate to high heterogeneity → More consistent research is needed.
1
0
0
📚 Methodology We followed PRISMA guidelines and performed a systematic review + meta-analysis: ✔️ 4 studies ✔️ 475 patients ✔️ Focus: Survival, safety, adverse events 🛠️ Software: RevMan v5.4
1
0
0
🎯 What’s it about? Uveal melanoma is a rare, aggressive eye cancer with few effective treatments — especially when metastatic. We analyzed the evidence for a new immunotherapy: Tebentafusp.
1
0
0